Revolutionizing Addiction Treatment: A Comparative Analysis of ReNAD Biologics’ NAD+ Therapy and Traditional Buprenorphine Protocols - Abstract
n an era where the opioid crisis is intensified by escalating fentanyl overdoses and daunting rehabilitation relapse rates, this pioneering study introduces
ReNAD Biologics’ ReNAD FTP-875 as a beacon of hope. Through a meticulous comparison with established buprenorphine treatments using the Clinical Opiate
Withdrawal Scale (COWS), we unveil a groundbreaking reduction in withdrawal symptoms, heralding a new era in addiction medicine.